CMBI: Raises SBP GROUP (01177) Target Price to HK$9, Maintains "Buy" Rating

date
15:15 18/11/2026
avatar
GMT Eight
CMBI stated that SBP GROUP has recently continued to achieve breakthroughs in both the commercialization and internationalization of innovative drugs.
CMBI issued a research report stating that SBP GROUP (01177) has recently continued to achieve breakthroughs in both the commercialization and internationalization of innovative drugs. Considering the company's continued BD transaction realizations in 2026, the bank raised its forecasts, expecting revenue to grow by 11.5%, 13.2%, and 10.4% year-on-year in 2026 to 2028, respectively, and adjusted net profit attributable to shareholders to grow by 12.5%, 19.4%, and 9.9% year-on-year, respectively. The bank maintained its "Buy" rating and raised its target price from HK$8.7 to HK$9. On November 14, 2026, the National Healthcare Security Administration announced the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)," under which the company's core subsidiary Chia Tai Tianqing had 3 innovative drugs included in the catalog for the first time, new indications for 2 innovative drugs included in the catalog, and 2 innovative drugs successfully renewed. The report noted that the company also recently reached a platform-type BD collaboration with multinational pharmaceutical company Boehringer Ingelheim (BI), involving US$358 million in upfront and near-term payments, total potential value of approximately US$7 billion, and double-digit sales royalties, continuing the strong trend of the company's continued realization of external collaborations in 2026. The bank believes that the medical insurance expansion is expected to accelerate the commercial conversion of SBP GROUP's innovative products, while the collaboration with BI validates the value of the company's early research platform and consolidates the long-term growth foundation of its innovative business.